Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
IPO Year: 2016
Exchange: NYSE
Website: myovant.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/26/2022 | Outperform → In-line | Evercore ISI | |
| 8/9/2022 | $12.00 → $23.00 | Mkt Perform → Outperform | SVB Leerink |
| 2/16/2022 | $21.00 → $19.00 | Market Perform | SVB Leerink |
| 1/5/2022 | $23.00 → $21.00 | Market Perform | SVB Leerink |
| 10/27/2021 | $24.00 → $23.00 | Market Perform | SVB Leerink |
| 9/9/2021 | $24.00 | Market Perform | SVB Leerink |
| 8/20/2021 | $18.00 | Neutral | Goldman |